-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。LPLAは2026年第1四半期決算を発表し、売上高は35%増の59億4,000万ドル（市場予想を6,000万ドル下回る）、調整後EPSは5.60ドルで、市場予想を0.13ドル上回りました。資産運用事業の変革は加速し、アドバイザリー事業の売上高は26億2,000万ドル（55%増）、アドバイザリー資産は1兆3,900億ドル（42%増）に達し、顧客資産総額の59.5%を占めるようになりました。当社は、LPLAの手数料ベースサービスへの戦略的転換が、より安定した収益基盤の構築と営業レバレッジの向上につながり、アドバイザリーおよびブローカー業務の総資産は2兆3,400億ドル（30%増）に達すると考えています。経営陣は、コモンウェルス関連費用を含め、2026年のコア一般管理費見通しの上限を2,000万ドル引き下げ、21億6,000万ドル～21億9,000万ドルとした。コモンウェルス買収は、資産保有率90%、更新後の年間EBITDA4億1,000万ドルで、2026年第4四半期の完了に向けて順調に進んでいる。LPLAは、5億6,700万ドルの現金と1.86倍のレバレッジ比率により、成長戦略のための十分な財務的柔軟性を維持しており、2026年第2四半期には推定1億2,500万ドルの自社株買いを再開する計画であると予想される。
Related Articles
Research
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
$HLT
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
$UHS
Asia
Shenghe Resources' Q1 Profit Jumps 94%, Revenue Climbs 13%
Shenghe Resources' (SHA:600392) net profit attributable to shareholders in the first quarter jumped 94% to 327.3 million yuan from 168.3 million yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share rose year on year to 0.1867 yuan from 0.0960 yuan.The Chinese rare earth miner's operating revenue climbed 13% to 3.38 billion yuan from 2.99 billion yuan in the previous year.
$SHA:600392